ACTIONS: Anti depressant Controlled Trial fOr Negative symptons in Schizophrenia
|Funding:||Health Technology Assessment Programme|
|Collaborators:||Dept of Psychological Medicine, Imperial College Hospital|
The main aim of the study is to establish the clinical and cost-effectiveness of the SSRI antidepressant, citalopram, in the management of negative symptoms of schizophrenia. The research hypothesis to be tested is that augmentation of stable antipsychotic medication with citalopram, is clinically and cost-effective for ameliorating persistent negative symptoms in schizophrenia and is not associated with an additional side effect burden.